These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
919 related articles for article (PubMed ID: 11694790)
1. HER2 as a prognostic factor in breast cancer. Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790 [TBL] [Abstract][Full Text] [Related]
2. Luminal B breast tumors are not HER2 positive. Bhargava R; Dabbs DJ Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725 [No Abstract] [Full Text] [Related]
3. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast]. Yang M; Xu SP; Ao QL Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534 [TBL] [Abstract][Full Text] [Related]
4. 14-3-3ζ promoted invasion and lymph node metastasis of breast invasive ductal carcinoma with HER2 overexpression. Wan D; Zhang Y; Yu Q; Li F; Zhuo J Pathol Res Pract; 2021 Nov; 227():153619. PubMed ID: 34560418 [TBL] [Abstract][Full Text] [Related]
5. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression. Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637 [TBL] [Abstract][Full Text] [Related]
6. Correlation of the ultrasound imaging of breast cancer and the expression of molecular biological indexes. Xu J; Li F; Chang F Pak J Pharm Sci; 2017 Jul; 30(4(Suppl.)):1425-1430. PubMed ID: 29043992 [TBL] [Abstract][Full Text] [Related]
7. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast. Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608 [TBL] [Abstract][Full Text] [Related]
8. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women]. Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090 [No Abstract] [Full Text] [Related]
9. p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women. Mao XY; Fan CF; Zheng HC; Wei J; Yao F; Jin F J Exp Clin Cancer Res; 2010 Aug; 29(1):112. PubMed ID: 20712900 [TBL] [Abstract][Full Text] [Related]
10. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031 [TBL] [Abstract][Full Text] [Related]
11. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer. Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721 [TBL] [Abstract][Full Text] [Related]
12. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions]. Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827 [TBL] [Abstract][Full Text] [Related]
13. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor. Xu S; Wei B; Zhang H; Qing M; Bu H Oncol Rep; 2008 Jun; 19(6):1469-75. PubMed ID: 18497952 [TBL] [Abstract][Full Text] [Related]
14. Early (<10 mm) HER2-Positive Invasive Breast Carcinomas are Associated with Extensive Diffuse High-Grade DCIS: Implications for Preoperative Mapping, Extent of Surgical Intervention, and Disease-Free Survival. Tot T Ann Surg Oncol; 2015 Aug; 22(8):2532-9. PubMed ID: 25582746 [TBL] [Abstract][Full Text] [Related]
15. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications. Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752 [TBL] [Abstract][Full Text] [Related]
16. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast]. Sánchez Salmón A; Argibay S; Arias JI; Ruibal A Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785 [TBL] [Abstract][Full Text] [Related]
17. [Prognostic factors of breast cancer]. Tang P; Wei B; Yang WJ; Liu YS; Bu H Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):73-6. PubMed ID: 21426799 [No Abstract] [Full Text] [Related]
18. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Arpino G; Bardou VJ; Clark GM; Elledge RM Breast Cancer Res; 2004; 6(3):R149-56. PubMed ID: 15084238 [TBL] [Abstract][Full Text] [Related]
19. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Leong AS; Sormunen RT; Vinyuvat S; Hamdani RW; Suthipintawong C Am J Clin Pathol; 2001 May; 115(5):709-18. PubMed ID: 11345835 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast. Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]